January 22, 2018 / 1:17 PM / a month ago

BUZZ-Vical: Falls as herpes vaccine fails late-stage trial

** Drugmaker’s shares fall 27.81 pct to $1.35 - top pct loser among Nasdaq-listed stocks premarket

** Tokyo-listed Astellas Pharma and Vical said its herpes vaccine, ASP0113, did not meet the main and secondary goals in a late-stage study

** Companies said the vaccine did not demonstrate a significant improvement in overall survival of patients under the trial program

** ASP0113, a vaccine to prevent herpes reactivation in stem cell transplant recipients, has “orphan” drug status in the United States and Europe

** Brokerage H.C. Wainwright cuts PT to $5 from $6; median PT is $5.10 - TR data

** Up to Friday’s close, stock had fallen 15.4 pct in the past twelve months (Reporting by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below